605 Neoadjuvant Endocrine Therapy vs Neoadjuvant Chemotherapy in Early Breast Cancer: A Systematic Review of Surgical Outcomes
British Journal of Surgery · 10.07.2026 · 113 (Supplement_6)
DOI: 10.1093/bjs/znag063.096 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift British Journal of Surgery, online erschienen am 10.07.2026. Verfasst von A Lowndes und 1 weiteren Autor:innen.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Aim
To systematically review the current evidence comparing neoadjuvant endocrine therapy (NET) versus neoadjuvant chemotherapy (NAC) in relation to surgical downstaging, pathological response, and survival outcomes in hormone receptor-positive/HER2-negative (HR+/HER2-) early breast cancer.
Method
A comprehensive systematic review was conducted by searching PubMed, Medline, and Cochrane Library databases, which initially yielded 324 results. Following rigorous screening and eligibility assessment, seven studies were ultimately included for synthesis: three randomised controlled trials (RCTs) and four large observational cohort studies. Data extraction focused on key surgical endpoints, including breast-conserving surgery (BCS) rates, mastectomy rates, pathological complete response (pCR), axillary lymph node dissection (ALND) rates, and overall survival (OS).
Results
The review demonstrates a consistent divergence between pathological and surgical outcomes. Across all included studies, NAC consistently achieved higher rates of pCR. However, evidence from extensive observational studies (totalling over 26,000 patients) suggests NET is associated with superior surgical de-escalation, leading to significantly lower mastectomy rates, and reduced post-lumpectomy radiation. RCTs confirmed that NET was non-inferior to NAC regarding both BCS rates and overall survival in node-positive patients. Systematic findings indicated no significant difference in ALND rates or overall survival between the two treatment groups after adjustment for clinical variables.
Conclusions
NET is a highly effective, non-inferior alternative to NAC in managing HR+/HER2- early breast cancer. It consistently facilitates breast conservation and minimises surgical extent with comparable survival outcomes, despite achieving lower pCR rates. NET should be prioritised as a de-escalation strategy for eligible patients.
Zitieren
APA
Lowndes, A., & Vithyakaran, T. (2026). 605 Neoadjuvant Endocrine Therapy vs Neoadjuvant Chemotherapy in Early Breast Cancer: A Systematic Review of Surgical Outcomes. British Journal of Surgery, 113(Supplement_6). https://doi.org/10.1093/bjs/znag063.096
Vancouver
Lowndes A, Vithyakaran T. 605 Neoadjuvant Endocrine Therapy vs Neoadjuvant Chemotherapy in Early Breast Cancer: A Systematic Review of Surgical Outcomes. British Journal of Surgery. 2026;113(Supplement_6). doi:10.1093/bjs/znag063.096
BibTeX
@article{Lowndes2026,
author = {Lowndes, A and Vithyakaran, T},
title = {605 Neoadjuvant Endocrine Therapy vs Neoadjuvant Chemotherapy in Early Breast Cancer: A Systematic Review of Surgical Outcomes},
journal = {British Journal of Surgery},
year = {2026},
volume = {113},
number = {Supplement_6},
doi = {10.1093/bjs/znag063.096}
}
EUVIMED